AstraZeneca tie-up worth up to $870m to sodium-diverting Ardelyx
This article was originally published in Scrip
A young Californian firm focused on developing drugs that can alter the uptake of minerals in the gut has snared AstraZeneca in a partnership that will see it receive $35 million up front, and up to $870 million in total. The UK group has signed an exclusive worldwide licence to a Phase II-ready first-in-class lead programme targeting sodium uptake with various potential applications developed by Ardelyx, of Fremont, along with several related compounds in discovery. It has agreed to pay up to $237.5 million in development milestones, plus launch and commercialisation milestones and tiered double-digit royalties.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.